SenseTime’s AI Healthcare Venture Secures $141 Million to Transform Medical AI

In the last six months, SenseTime’s newly established AI healthcare subsidiary has successfully raised $141 million, signaling strong investor confidence in its mission to revolutionize healthcare through artificial intelligence. The company unveiled its ambitious plan to create a comprehensive “medical world model” that integrates cutting-edge AI technologies across hospitals, research institutions, and global markets.

Strategic Vision: Building the Hospital of Tomorrow

December 2025 marked the debut public presentation of SenseTime’s healthcare spin-off, where it outlined its dual role as both an innovator and enabler of the “future hospital.” The company’s Series A funding round has officially commenced, supported by prominent backers including Yingfeng Holding, affiliated with Midea, and the People’s Medical Publishing House Technology. This new entity will benefit from extensive technical and strategic support from SenseTime’s broader “1+X” ecosystem, positioning it as a pivotal extension of the group’s AI ambitions.

Innovative AI Architecture and Medical Language Model

The company’s AI framework combines general-purpose and specialized components, anchored by its proprietary medical large language model, DaYi® (“Great Doc”). This model orchestrates a suite of multimodal foundational models alongside a vast medical database. DaYi® leads industry benchmarks, excelling in eight professional evaluation categories thanks to its training on an extensive medical corpus exceeding 400 billion Chinese characters. Utilizing an industrial-grade Retrieval-Augmented Generation (RAG) framework and rigorous clinical reasoning training, DaYi® significantly minimizes hallucinations and enhances diagnostic precision in complex medical scenarios.

Complementing this, the company has developed two integrated middle-office platforms that facilitate the creation of AI agents and the production of medical imaging AI solutions. These platforms have already birthed three standardized AI products, underscoring the company’s rapid innovation cycle.

Comprehensive AI Solutions for Smart Hospitals

Leveraging its core technologies, the company launched SenseCare® Smart Hospital solutions, which encompass clinical care, patient services, research support, and cloud infrastructure. Currently, over 40 AI modules are operational within clinical settings. For example, its AI-powered pathology diagnostic system boosts efficiency by 30-50%, while an intelligent liver surgery decision support system-developed in partnership with Tsinghua University’s Chang Gung Hospital-streamlines the entire surgical process.

Patient-facing services include streamlined appointment scheduling, treatment management, and mobile health monitoring. Additionally, the DaYi Research Assistant offers comprehensive support to medical researchers, assisting with tasks such as manuscript drafting and literature review.

Successful Deployments and Expanding Global Footprint

Commercial applications have demonstrated tangible benefits. Collaborating with Ruijin Hospital, the company developed the “Ruijin Digital Human,” an AI system that has supported over 400 complex liver surgeries. Its research platform, created in partnership with Roche Pharmaceuticals, now serves 700 top-tier hospitals, saving more than 20,000 research hours to date.

Further, the company is working with Shanghai Shenkang to establish China’s largest big-data medical training center. Its AI products have been integrated into Lenovo’s omnichannel ecosystem and deployed across medical institutions affiliated with the Midea Group.

Internationally, the company has accelerated its expansion by securing Singapore’s first AI medical device certification, with hospital implementations underway. It has also initiated its first project in Indonesia, marking a significant step in its global outreach.

Future Directions: Toward a Holistic Medical World Model

Looking ahead, the company aims to evolve its AI capabilities beyond question-answering to simulate clinical outcomes and support complex decision-making processes. This vision aligns with SenseTime’s broader “1+X” strategy, which recently achieved breakthroughs in spatial intelligence technologies.

Key executives from the group are slated to lead discussions at CVPR 2026, focusing on advancements in medical imaging and other cutting-edge AI applications in healthcare.